Tyvaso DPI™ (inhaled treprostinil)
Treprostinil inhalation powder
ROUTE OF ADMINISTRATION
Phase 3 BREEZE and pivotal pharmacokinetic studies completed; NDA planned for first half of 2021
Tyvaso DPI is an investigational combination product that is not approved for any use in any country, and the Tyvaso DPI tradename is pending FDA review.